Literature DB >> 9176543

Anti-interleukin 5 strategies as a potential treatment for asthma.

A D Singh1, C J Sanderson.   

Abstract

A paradigm shift, championed largely by cellular immunologists, has redefined asthma as an immune mediated phenomenon characterised by an interleukin 5 (IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense interest in the possibility that inhibitors of IL-5 production, or antagonists of its activity, will provide a new generation of anti-asthma drugs.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9176543      PMCID： PMC1758563          DOI： 10.1136/thx.52.5.483

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  7 in total

1.  The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice.

Authors:  M Korenaga; Y Hitoshi; N Yamaguchi; Y Sato; K Takatsu; I Tada
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

Review 2.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

Review 3.  How is expression of the interleukin-5 gene regulated?

Authors:  S Karlen; V A Mordvinov; C J Sanderson
Journal:  Immunol Cell Biol       Date:  1996-04       Impact factor: 5.126

4.  In vivo administration of antibody to murine IL-5 receptor inhibits eosinophilia of IL-5 transgenic mice.

Authors:  Y Hitoshi; N Yamaguchi; M Korenaga; S Mita; A Tominaga; K Takatsu
Journal:  Int Immunol       Date:  1991-02       Impact factor: 4.823

Review 5.  Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.

Authors:  R W Egan; D Athwahl; C C Chou; S Emtage; C H Jehn; T T Kung; P J Mauser; N J Murgolo; M W Bodmer
Journal:  Int Arch Allergy Immunol       Date:  1995 May-Jun       Impact factor: 2.749

6.  Eosinophilia in transgenic mice expressing interleukin 5.

Authors:  L A Dent; M Strath; A L Mellor; C J Sanderson
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

7.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.

Authors:  P S Foster; S P Hogan; A J Ramsay; K I Matthaei; I G Young
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307
  7 in total
  3 in total

Review 1.  Novel drugs for treating asthma.

Authors:  T T Hansel; P J Barnes
Journal:  Curr Allergy Asthma Rep       Date:  2001-03       Impact factor: 4.806

Review 2.  New ideas on the pathophysiology and treatment of lung disease.

Authors:  D F Rogers; G J Laurent
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 3.  Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle.

Authors:  Sue McKay; Hari S Sharma
Journal:  Respir Res       Date:  2001-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.